Cargando…
Can GPR4 Be a Potential Therapeutic Target for COVID-19?
Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859652/ https://www.ncbi.nlm.nih.gov/pubmed/33553219 http://dx.doi.org/10.3389/fmed.2020.626796 |
_version_ | 1783646781190438912 |
---|---|
author | Yang, Li V. Oppelt, Karen A. Thomassen, Mary Jane Marie, Mona A. Nik Akhtar, Shayan McCallen, Justin D. |
author_facet | Yang, Li V. Oppelt, Karen A. Thomassen, Mary Jane Marie, Mona A. Nik Akhtar, Shayan McCallen, Justin D. |
author_sort | Yang, Li V. |
collection | PubMed |
description | Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely from asymptomatic infection, mild respiratory illness to severe pneumonia with respiratory failure and death. Autopsy studies demonstrate that diffuse alveolar damage, inflammatory cell infiltration, edema, proteinaceous exudates, and vascular thromboembolism in the lung as well as extrapulmonary injuries in other organs represent key pathological findings. Herein, we hypothesize that GPR4 plays an integral role in COVID-19 pathophysiology and is a potential therapeutic target for the treatment of COVID-19. GPR4 is a pro-inflammatory G protein-coupled receptor (GPCR) highly expressed in vascular endothelial cells and serves as a “gatekeeper” to regulate endothelium-blood cell interaction and leukocyte infiltration. GPR4 also regulates vascular permeability and tissue edema under inflammatory conditions. Therefore, we hypothesize that GPR4 antagonism can potentially be exploited to mitigate the hyper-inflammatory response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular thromboembolism and tissue injury associated with COVID-19. |
format | Online Article Text |
id | pubmed-7859652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78596522021-02-05 Can GPR4 Be a Potential Therapeutic Target for COVID-19? Yang, Li V. Oppelt, Karen A. Thomassen, Mary Jane Marie, Mona A. Nik Akhtar, Shayan McCallen, Justin D. Front Med (Lausanne) Medicine Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become a global pandemic. SARS-CoV-2 infection causes damages to the lung and other organs. The clinical manifestations of COVID-19 range widely from asymptomatic infection, mild respiratory illness to severe pneumonia with respiratory failure and death. Autopsy studies demonstrate that diffuse alveolar damage, inflammatory cell infiltration, edema, proteinaceous exudates, and vascular thromboembolism in the lung as well as extrapulmonary injuries in other organs represent key pathological findings. Herein, we hypothesize that GPR4 plays an integral role in COVID-19 pathophysiology and is a potential therapeutic target for the treatment of COVID-19. GPR4 is a pro-inflammatory G protein-coupled receptor (GPCR) highly expressed in vascular endothelial cells and serves as a “gatekeeper” to regulate endothelium-blood cell interaction and leukocyte infiltration. GPR4 also regulates vascular permeability and tissue edema under inflammatory conditions. Therefore, we hypothesize that GPR4 antagonism can potentially be exploited to mitigate the hyper-inflammatory response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular thromboembolism and tissue injury associated with COVID-19. Frontiers Media S.A. 2021-01-21 /pmc/articles/PMC7859652/ /pubmed/33553219 http://dx.doi.org/10.3389/fmed.2020.626796 Text en Copyright © 2021 Yang, Oppelt, Thomassen, Marie, Nik Akhtar and McCallen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Yang, Li V. Oppelt, Karen A. Thomassen, Mary Jane Marie, Mona A. Nik Akhtar, Shayan McCallen, Justin D. Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title | Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title_full | Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title_fullStr | Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title_full_unstemmed | Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title_short | Can GPR4 Be a Potential Therapeutic Target for COVID-19? |
title_sort | can gpr4 be a potential therapeutic target for covid-19? |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859652/ https://www.ncbi.nlm.nih.gov/pubmed/33553219 http://dx.doi.org/10.3389/fmed.2020.626796 |
work_keys_str_mv | AT yangliv cangpr4beapotentialtherapeutictargetforcovid19 AT oppeltkarena cangpr4beapotentialtherapeutictargetforcovid19 AT thomassenmaryjane cangpr4beapotentialtherapeutictargetforcovid19 AT mariemonaa cangpr4beapotentialtherapeutictargetforcovid19 AT nikakhtarshayan cangpr4beapotentialtherapeutictargetforcovid19 AT mccallenjustind cangpr4beapotentialtherapeutictargetforcovid19 |